ERBB2 and neoplasm: Combined treatments with salinomycin, conventional drugs (i.e., doxorubicin or paclitaxel), anti-HER2 targeted therapies (monoclonal antibody trastuzumab and lapatinib), and histone deacetylase inhibitors synergistically counteracted tumor growth [185,186].